Last Updated: 2026-03-21
DAT (Dopamine Transporter) scan imaging is a nuclear medicine technique used to visualize dopamine transporter binding in the brain. It is a crucial diagnostic tool for differentiating Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB) from other movement disorders like essential tremor[1][2]. This imaging modality has revolutionized the differential diagnosis of parkinsonian syndromes by providing objective evidence of presynaptic dopaminergic neurodegeneration.
Dopamine transporters are membrane proteins located on the presynaptic terminals of dopaminergic neurons in the substantia nigra pars compacta (SNpc) that project to the striatum (caudate nucleus and putamen). These transporters are responsible for the reuptake of dopamine from the synaptic cleft, playing a critical role in modulating dopaminergic neurotransmission[3]. In neurodegenerative parkinsonian syndromes, the loss of dopaminergic neurons leads to a corresponding reduction in DAT density, which can be visualized using SPECT or PET imaging with appropriate radioligands[4].
| Condition | DAT Scan Pattern | Clinical Correlation |
|---|---|---|
| Normal | Symmetric uptake in caudate and putamen | Non-degenerative movement disorder |
| Parkinson's Disease | Asymmetric reduction, putamen worse than caudate | Dopaminergic neuron loss in SNpc |
| Dementia with Lewy Bodies | Diffuse reduction in caudate and putamen | Widespread neurodegeneration |
| Progressive Supranuclear Palsy | Moderate diffuse reduction | Tau pathology in basal ganglia |
| Multiple System Atrophy | Variable pattern, often asymmetric | Mixed pathology with autonomic involvement |
| Corticobasal Degeneration | Asymmetric reduction | Tau pathology affecting cortical-subcortical circuits |
DAT imaging employs several radiopharmaceuticals that bind to dopamine transporters:
I-123 Ioflupane (DaTscan/FP-CIT):
Other DAT Ligands:
SPECT (Single-Photon Emission Computed Tomography):
PET (Positron Emission Tomography):
Patient Preparation:
Radiotracer Administration:
Image Acquisition:
Image Analysis:
DAT scans are primarily indicated for:
Distinguishing Parkinson's Disease from Essential Tremor:
Differentiating Parkinsonian Syndromes:
Early Parkinson's Disease Detection:
DAT imaging plays a crucial role in distinguishing:
Dementia with Lewy Bodies vs Alzheimer's Disease:
Parkinson's Disease Dementia vs Alzheimer's Disease:
DAT imaging can identify:
SWEDD (Scans Without Evidence of Dopaminergic Deficit):
Premotor Parkinson's Disease:
The striatal binding ratio is calculated as:
SBR = (Striatal Counts - Background) / Background
| Region | Normal | Early PD | Advanced PD |
|---|---|---|---|
| Caudate | 2.5-3.5 | 2.0-2.5 | 1.5-2.0 |
| Putamen | 2.0-3.0 | 1.0-1.5 | 0.5-1.0 |
| Caudate/Putamen Ratio | 1.0-1.2 | 1.5-2.5 | 2.0-3.0 |
AI = (|Left - Right| / (Left + Right)) times 100%
Clinical Presentation: 58-year-old male with 2-year history of right hand tremor and bradykinesia.
DAT Scan Findings:
Interpretation: Abnormal DAT scan consistent with presynaptic dopaminergic degeneration. Findings support clinical diagnosis of Parkinson's disease.
Clinical Presentation: 65-year-old female with 10-year history of bilateral hand tremor, worsened with posture and movement.
DAT Scan Findings:
Interpretation: Normal DAT scan indicates intact presynaptic dopaminergic system. Tremor is likely essential tremor, not degenerative parkinsonism.
Clinical Presentation: 72-year-old male with progressive dementia, visual hallucinations, and parkinsonism.
DAT Scan Findings:
Interpretation: Abnormal DAT scan with diffuse pattern suggests Dementia with Lewy Bodies. The diffuse pattern distinguishes DLB from Parkinson's disease.
DAT scan results influence clinical management:
Antiparkinsonian Therapy:
Prognostic Counseling:
Clinical Trial Enrollment:
DAT imaging can track:
Neurodegeneration Rate:
Treatment Effects:
Radiation Exposure:
Limited Spatial Resolution:
Variability:
Cannot Determine Etiology:
Not Always Binary:
Late Changes:
| Feature | DAT Scan | MIBG Scan |
|---|---|---|
| Target | Dopamine transporter | Sympathetic innervation |
| Pathology | Presynaptic nigrostriatal | Postganglionic sympathetic |
| PD Finding | Reduced uptake | Reduced uptake |
| DLB | Reduced uptake | Reduced uptake |
| AD | Normal | Normal |
| PSP | Reduced | Usually normal |
| MSA | Reduced | Variable |
Recent advances in DAT imaging include:
Improved Resolution:
Multimodal Imaging:
Quantification Advances:
Screening Applications:
Personalized Medicine:
Bajaj et al. DaTscan in Parkinsonian syndromes. Journal of Neurology Neurosurgery and Psychiatry. 2020. ↩︎
Arena et al. DAT imaging in Parkinson's disease diagnosis. Journal of Neurology Neurosurgery and Psychiatry. 2020. ↩︎
Vaughan and Foster, Dopamine transporter biology and function. Handbook of Clinical Neurology. 2013. ↩︎
Jankovic et al. DAT imaging in movement disorders. Movement Disorders. 2018. ↩︎
Koch et al. I-123 ioflupane SPECT standardized reference values. European Journal of Nuclear Medicine and Molecular Imaging. 2015. ↩︎
Zubov et al. Novel DAT PET ligands for neurodegeneration imaging. Journal of Nuclear Medicine. 2024. ↩︎
Darcourt et al. EANM practice guideline for DAT SPECT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2020. ↩︎
Matsuda et al. DAT PET in Parkinson's disease. Annals of Nuclear Medicine. 2023. ↩︎
Morbelli et al. EANM practice guideline for quantitative DAT SPECT. European Journal of Nuclear Medicine and Molecular Imaging. 2022. ↩︎
Bajaj et al. Diagnostic accuracy of DAT SPECT for parkinsonism. Neurology. 2020. ↩︎
Nicastro et al. DAT pattern in atypical parkinsonian syndromes. Parkinsonism and Related Disorders. 2020. ↩︎
Pavese and Brooks, Neuroimaging of prodromal Parkinson disease. Nature Reviews Neurology. 2021. ↩︎
McKeith et al. DLB diagnostic criteria and DAT imaging. Lancet Neurology. 2022. ↩︎
Albert et al. DAT imaging in Parkinson disease dementia. Neurology. 2023. ↩︎
Marek et al. SWEDD subjects in Parkinson's disease cohorts. Brain. 2018. ↩︎
Iranzo et al. DAT imaging in isolated RBD. Annals of Neurology. 2022. ↩︎
Tossici-Bolt et al. Quantitative analysis of DAT SPECT. Neuroimage. 2006. ↩︎
Ryu et al. Asymmetry analysis in DAT SPECT for PD. Journal of Clinical Neurology. 2022. ↩︎
Pavese et al. DAT imaging as biomarker in clinical trials. Lancet Neurology. 2024. ↩︎
Whone et al. DAT imaging for disease progression monitoring. Movement Disorders. 2024. ↩︎
Matsunari et al. Pitfalls in DAT SPECT interpretation. Radiographics. 2021. ↩︎
Kahraman et al. Limitations of DAT imaging in early PD. Parkinsonism and Related Disorders. 2023. ↩︎
Seibyl et al. F-18 DAT PET for early Parkinson's detection. Journal of Nuclear Medicine. 2024. ↩︎
Okada et al. Early-frame F-18 PET for DAT imaging. European Journal of Nuclear Medicine and Molecular Imaging. 2025. ↩︎
Albert et al. Dual-tracer PET for dementia differential diagnosis. Alzheimer's and Dementia. 2025. ↩︎
Huang et al. Machine learning for DAT SPECT classification. Neuroimage Clinical. 2024. ↩︎
Matsuda et al. DAT imaging for deep brain stimulation planning. Stereotactic and Functional Neurosurgery. 2024. ↩︎
Bucher et al. Future of DAT imaging in neurodegeneration. European Journal of Nuclear Medicine and Molecular Imaging. 2026. ↩︎